Another deal impacting the Pharma logistics space this week with rumoured former World Courier suitor UPS agreeing to stump up €5.2bn ($6.8bn) for Dutch rival TNT Express NV.
Indian API manufacturers may dominate the list of companies that have had CEPs suspended this year, but that may say more about inspection policies than it does about standards outside Europe.
Quintiles has inked a deal with Delcath which will see it deploy a team of medical experts to support the European launch of the Hepatic Chemosat Delivery system.
Generics and API maker Ranbaxy has opened a plant in Casablanca, Morocco in a bid to strengthen its foothold in the “increasingly important” North African drugs market.
GSK will launch an apprenticeship programme later this year to train young people in a range of industry disciplines, including manufacturing, R&D and supply chain management.
Quintiles has added to its commercial services capabilities in the Middle East and North Africa (MENA) region through an agreement with UAE-based Dayarn Pharma.
Lonza has denied reports it has signed a deal with the South African government to build a $210m (€159m) API plant, saying it is merely “in discussions” over plans.
BASF has hiked its prices for ethanolamines just days after asking the European Commission to review measures designed to stop US exporters selling the compound to manufacturers in Europe at less than cost.
Russia’s trial sector has largely recovered from the ‘crisis’ created by revision of approval system in 2010, but regulators are still taking too long to OK studies says industry group ACTO.
HUYA Bioscience says it will strengthen bonds between Chinese drug innovators and worldwide developers and through its new partnership with the Tianjin Institute of Pharmaceutical Research (TIPR).
Clinical research associates (CRAs) spend less than half of their time conducting ‘on site’ monitoring with training, travel and admin taking up the majority of their time according to new research
Quintiles has invested £3m ($4.6m) in a new UK-based biomarker R&D company in a continuation of its efforts to build in the field of personalised medicines.
ACRO says latest draft rules on trials in India – which would see ethics committees take sole responsibility for determining SAE cause and compensation - are a backwards step that would make high quality research impossible.
